Pharmsville Past Earnings Performance
Past criteria checks 0/6
Pharmsville's earnings have been declining at an average annual rate of -21.4%, while the Personal Products industry saw earnings growing at 13.8% annually. Revenues have been declining at an average rate of 15.5% per year. Pharmsville's return on equity is 1.4%, and it has net margins of 5.1%.
Key information
-21.4%
Earnings growth rate
-23.2%
EPS growth rate
| Personal Products Industry Growth | 3.8% |
| Revenue growth rate | -15.5% |
| Return on equity | 1.4% |
| Net Margin | 5.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Some Pharmsville Co., Ltd. (KOSDAQ:318010) Shareholders Look For Exit As Shares Take 26% Pounding
Dec 09
Unpleasant Surprises Could Be In Store For Pharmsville Co., Ltd.'s (KOSDAQ:318010) Shares
Oct 14Pharmsville's (KOSDAQ:318010) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Mar 28Pharmsville (KOSDAQ:318010) Has A Pretty Healthy Balance Sheet
Mar 31We're Watching These Trends At Pharmsville (KOSDAQ:318010)
Mar 03Pharmsville's (KOSDAQ:318010) Shareholders Are Down 20% On Their Shares
Feb 10
Factors Income Investors Should Consider Before Adding Pharmsville Co., Ltd. (KOSDAQ:318010) To Their Portfolio
Jan 20Here's Why Pharmsville (KOSDAQ:318010) Can Manage Its Debt Responsibly
Dec 24Is Pharmsville Co., Ltd. (KOSDAQ:318010) A High Quality Stock To Own?
Nov 26Revenue & Expenses Breakdown
How Pharmsville makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 17,923 | 922 | 9,439 | 2,297 |
| 30 Jun 24 | 19,038 | 1,647 | 9,108 | 2,122 |
| 31 Mar 24 | 20,213 | 2,750 | 8,926 | 2,213 |
| 31 Dec 23 | 21,395 | 3,310 | 9,075 | 2,187 |
| 30 Sep 23 | 22,923 | 3,609 | 8,794 | 1,548 |
| 30 Jun 23 | 24,682 | 4,179 | 9,380 | 1,635 |
| 31 Mar 23 | 26,208 | 4,386 | 10,029 | 1,630 |
| 31 Dec 22 | 26,113 | 4,063 | 9,811 | 1,661 |
| 30 Sep 22 | 26,426 | 3,279 | 10,298 | 1,750 |
| 30 Jun 22 | 28,417 | 4,147 | 11,373 | 1,599 |
| 31 Mar 22 | 33,678 | 4,928 | 14,481 | 1,315 |
| 31 Dec 21 | 39,028 | 5,000 | 18,187 | 1,189 |
| 30 Sep 21 | 42,349 | 4,518 | 21,396 | 843 |
| 30 Jun 21 | 41,466 | 2,876 | 22,392 | 838 |
| 31 Mar 21 | 39,673 | 2,186 | 22,320 | 800 |
| 31 Dec 20 | 39,409 | 2,891 | 22,073 | 812 |
| 30 Sep 20 | 38,932 | 5,483 | 21,471 | 622 |
| 30 Jun 20 | 38,995 | 6,811 | 20,385 | 425 |
| 31 Mar 20 | 36,331 | 8,257 | 17,902 | 359 |
| 31 Dec 19 | 29,952 | 7,256 | 14,277 | 490 |
| 30 Jun 19 | 21,224 | 5,069 | 9,481 | 757 |
| 31 Mar 19 | 19,025 | 4,169 | 7,925 | 930 |
| 31 Dec 18 | 19,833 | 4,839 | 7,847 | 936 |
| 31 Dec 17 | 16,802 | 3,668 | 7,142 | 829 |
Quality Earnings: A318010 has a large one-off gain of ₩246.8M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: A318010's current net profit margins (5.1%) are lower than last year (15.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A318010's earnings have declined by 21.4% per year over the past 5 years.
Accelerating Growth: A318010's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A318010 had negative earnings growth (-74.5%) over the past year, making it difficult to compare to the Personal Products industry average (40.3%).
Return on Equity
High ROE: A318010's Return on Equity (1.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 09:16 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmsville Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyung-rae Han | Daishin Securities Co. Ltd. |
| Jongsun Park | Eugene Investment & Securities Co Ltd. |